Group items tagged

This award is designed to support young scientists just embarking on their independent research careers.  The applicants' research interests should be consonant with those of the March of Dimes' mission: The  Mission of the March of Dimes is to improve the health of babies by preventing birth defects, premature birth and infant mortality. The March of Dimes defines a birth defect as any abnormality of structure or function, whether inherited, or acquired in utero and presenting in infancy or early childhood. Deviations from reproductive health of women and men as an underlying basis of birth defects, i.e. preconceptional events, perinatal course, and premature births, are appropriate subjects for research support. Relevance is interpreted broadly to include fundamental cell biology (embryogenesis, cell lineage, differentiation), genetics and genomics, fundamental cellular and clinical pathogenesis of disorders of importance to mothers and infants, biomedical engineering and imaging, and social and behavioral aspects. Each application should be accompanied by a Letter of Support from a Nominator (see below). The award is $150,000 for two years, including 10 percent indirect costs to sponsoring institutions.

The purpose of this funding opportunity announcement (FOA) is to support the innovative biomedical and proof-of-concept research needed to understand how reproductive maturation or injury alters the mucosal environments at HIV susceptible sites. This information is essential to provide the safest and most efficacious biomedical prevention strategies (e.g., topical microbicides and Pre-Exposure Prophylaxis (PrEP), etc.) to those populations at heightened risk of HIV infection.  

The U.S. Environmental Protection Agency (EPA), as part of its Science to Achieve Results (STAR) program, is seeking applications proposing research that will promote the development and use of alternative test methods and strategies that address the "3Rs" of toxicity testing: 1) reduce, 2) refine, and/or 3) replace vertebrate animal testing. For the purposes of this RFA, alternative test methods refer to those that incorporate the "3Rs" principles. Pertinent research includes approaches such as analog/read-across techniques, mathematical models, and tiered testing approaches that integrate evidence from multiple sources to help accomplish these goals. In addition to the development of new alternative test methods and strategies, translational science approaches that use available data to develop and/or advance actionable approaches for risk assessment of chemicals are also critical. In this context, approaches that facilitate the use of existing animal data sources to reduce, refine, or replace the need for new vertebrate animal tests are as welcome as those that provide new data streams. The research activities to be funded under this announcement are intended to advance the science underpinning the use of non-vertebrate test methods, and to develop actionable alternative approaches to: 1) developmental toxicity tests in humans; 2) reproductive toxicity tests in humans; and/or 3) ecotoxicity tests.

Ferring is committed to building a portfolio of novel, innovative drugs to address the indications of high unmet medical need for patients in our core therapeutic areas of interest.   The Ferring Innovation Grants are awarded annually in January and are not renewable. We will NOT fund clinical studies, or studies which require the collection of human samples under the direction of an Institutional Review Board. Proposals should only include analysis of anonymized human samples collected independently of this application. Therapeutic areas of interest to Ferring include: - Gastroenterology & Hepatology - Reproductive Medicine & Women's Health - Urology - Biomarker Discovery

A primary focus of these programs is on the use of in vitro methods and assays using lower organisms to screen thousands of chemicals for toxicity in order to identify mechanisms of compound-induced biological activity, characterize toxicity pathways, facilitate cross-species extrapolation, and provide input to models for low-dose extrapolation.  Data generated by these methods will be used to prioritize compounds for more extensive toxicological evaluation and to develop predictive models for biological response in humans. Current approaches are limited in terms of incorporating genetic variability in toxicity testing and in assessing the effects of chemicals in multiple normal tissue and cell types, relying on immortalized cell lines or primary cell lines derived from tissues. Thus, there is a need for novel, medium- to high-throughput assays (at least a 96-well format) to evaluate the effects of chemical compounds on the differentiation of pluripotent or multi-potent stem cells as well as the effects of chemical exposures on differentiated cell types representative of various in vivo tissues. Approaches can include the use of human induced pluripotent stem (iPS) cells, approved human embryonic stem (ES) cell lines, or ES or iPS cells derived from genetically characterized mouse strains. Assays should be able to measure the effects of toxicants on the differentiation process and/or on the differentiated cells themselves; cell types of high priority include but are not limited to cardiomyocytes, neural cells, hepatocytes, endothelial cells, lung (airway or alveolar) cells, and hormonally-responsive tissues such as reproductive tissues or breast epithelial cells.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NICHD R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development, which are encouraged to include hands-on research experiences. This FOA encourages applications to develop and conduct short-term research education programs to improve the knowledge and research skills of biomedical and behavioral scientists conducting research in areas relevant to the mission of NICHD, including reproductive, developmental, behavioral, social, and rehabilitative processes that determine the health and well-being of newborns, infants, children, adults, families, and populations.

The primary purpose of the ASRM and SREI Research Grant Programs is to provide funds for new investigators to establish independent research programs. New investigators are those who have completed their training within the past three years and have independent faculty appointments at the commencement of the research. In special cases, ASRM will consider applications for bridge funding (i.e., between grant funding periods) for projects that are of benefit to other members of the Society, or for funding of new, highly innovative research projects by established investigators. Both the ASRM Research Grants, which are funded by the ASRM, and the SREI Research Grants, which are funded by SREI, are reviewed by the ASRM Research Committee. Grants in amounts of $10,000 to $50,000 will be considered for funding by the ASRM Board of Directors on an annual basis. A total of $200,000 is available for 2016. The SREI Board of Directors will fund one grant of up to $40,000. Funds are available for project expenses, technical assistance, patient expenses, research supplies and durable laboratory equipment. Up to ten percent (10%) of funds may be used for indirect costs or institutional overhead in circumstances deemed to be extraordinary by the Research Committee. Research grant funds may be expended over a 2-year time interval. If residual funds remain after 2 years, the principal investigator can apply for a no-cost extension. An individual should indicate which grant(s) he/she is applying for though he/she is eligible to receive only one grant.